J Korean Med Assoc.  2017 Sep;60(9):739-745. 10.5124/jkma.2017.60.9.739.

Present and future of oculoplasty

• Lee H

• KMID: 2389793
• DOI: http://doi.org/10.5124/jkma.2017.60.9.739

Abstract

Ophthalmic plastic and reconstructive surgery combines the precision of ophthalmic microsurgery with plastic and reconstructive surgical principles, allowing for subspecialized care of the eyelid, orbital, and lacrimal system. A foundation in ophthalmology allows the oculoplastic surgeon's knowledge and skills to safely and successfully protect the globe while achieving good functional and aesthetic results. Oculoplasty emerged following World War II, in which a high rate of ophthalmic and oculoplastic trauma occurred. Following this, more structured and specialized studies dedicated to clinical and surgical management led to the development of a highly specific and rapidly growing sub-specialty dedicated to eyelid, lacrimal, and orbital care. Stem cell treatments in oculoplasty has been spanned a wide array of subfields, ranging from reconstruction of the eyelid to the generation of artificial lacrimal glands and oncological therapeutics. Tissue engineering represents the future of regenerative and reconstructive medicine, with significant potential applications in ophthalmic plastic surgery. Difficulty remains in disease modeling for various disorders, owing to genetic and functional variation across patients as well as the complexity of several diseases. Progressive advances in the understanding of the immunopathogenesis of diseases such as thyroid eye disease and lacrimal gland carcinoma continue to spur clinical trials utilizing targeted therapies to enhance treatment outcomes. Continued investigation of the molecular mechanisms of disease will expand potential treatments. In the future, public awareness and interest in the field of oculoplasty will further grow, and personalized and optimized treatment will become a cornerstone of modern medicine.

Keyword

Lacrimal apparatus carcinoma; Stem cell; Thyroid associated ophthalmopathy; Tissue engineering

MeSH Terms

Eye Diseases
Eyelids
Graves Ophthalmopathy
History, Modern 1601-
Humans
Lacrimal Apparatus
Microsurgery
Ophthalmology
Orbit
Plastics
Stem Cells
Surgery, Plastic
Thyroid Gland
Tissue Engineering
World War II
Plastics

Reference

1. Saleh GM, Athanasiadis I, Collin JR. Training and oculoplastics: past, present and future. Orbit. 2013; 32:111–116.

2. Gauba V, Saleh GM, Goel S. Ophthalmic plastic surgical skills assessment tool. Ophthal Plast Reconstr Surg. 2008; 24:43–46.

3. Golnik KC, Gauba V, Saleh GM, Collin R, Naik MN, Devoto M, Nerad J. The ophthalmology surgical competency assessment rubric for lateral tarsal strip surgery. Ophthal Plast Reconstr Surg. 2012; 28:350–354.

4. Saleh GM, Gauba V, Sim D, Lindfield D, Borhani M, Ghoussayni S. Motion analysis as a tool for the evaluation of oculoplastic surgical skill: evaluation of oculoplastic surgical skill. Arch Ophthalmol. 2008; 126:213–216.

5. Saleh GM, Litwin A, Collin JR, Rose GE, Gauba V, Ghoussayni S, Hussain B. Kinematic analysis in oculoplastic reconstructive surgery: measuring manual control and fluidity of movement. Arch Ophthalmol. 2012; 130:1570–1574.

6. Daniel MG, Wu AY. Applications of stem cell biology to oculoplastic surgery. Curr Opin Ophthalmol. 2016; 27:428–432.

7. Kruse FE. Stem cells and corneal epithelial regeneration. Eye (Lond). 1994; 8(Pt 2):170–183.

8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126:663–676.

9. Hirayama M, Tsubota K, Tsuji T. Bioengineered lacrimal gland organ regeneration in vivo. J Funct Biomater. 2015; 6:634–649.

10. Trottier V, Marceau-Fortier G, Germain L, Vincent C, Fradette J. IFATS collection: using human adipose-derived stem/stromal cells for the production of new skin substitutes. Stem Cells. 2008; 26:2713–2723.

11. Cherubino M, Rubin JP, Miljkovic N, Kelmendi-Doko A, Marra KG. Adipose-derived stem cells for wound healing applications. Ann Plast Surg. 2011; 66:210–215.

12. Park BS, Jang KA, Sung JH, Park JS, Kwon YH, Kim KJ, Kim WS. Adipose-derived stem cells and their secretory factors as a promising therapy for skin aging. Dermatol Surg. 2008; 34:1323–1326.

13. Sun H, Liu W, Zhou G, Zhang W, Cui L, Cao Y. Tissue engineering of cartilage, tendon and bone. Front Med. 2011; 5:61–69.

14. Baino F. Biomaterials and implants for orbital floor repair. Acta Biomater. 2011; 7:3248–3266.

15. Dean D, Wolfe MS, Ahmad Y, Totonchi A, Chen JE, Fisher JP, Cooke MN, Rimnac CM, Lennon DP, Caplan AI, Topham NS, Mikos AG. Effect of transforming growth factor beta 2 on marrow-infused foam poly(propylene fumarate) tissue-engineered constructs for the repair of critical-size cranial defects in rabbits. Tissue Eng. 2005; 11:923–939.

16. Rohner D, Hutmacher DW, Cheng TK, Oberholzer M, Hammer B. In vivo efficacy of bone-marrow-coated polycaprolactone scaffolds for the reconstruction of orbital defects in the pig. J Biomed Mater Res B Appl Biomater. 2003; 66:574–580.

17. Schantz JT, Teoh SH, Lim TC, Endres M, Lam CX, Hutmacher DW. Repair of calvarial defects with customized tissue-engineered bone grafts I. Evaluation of osteogenesis in a three-dimensional culture system. Tissue Eng. 2003; 9:Suppl 1. S113–S126.

18. Zhou J, Peng SW, Wang YY, Zheng SB, Wang Y, Chen GQ. The use of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) scaffolds for tarsal repair in eyelid reconstruction in the rat. Biomaterials. 2010; 31:7512–7518.

19. Woo KI, Yeom A, Esmaeli B. Management of lacrimal gland carcinoma: lessons from the literature in the past 40 years. Ophthal Plast Reconstr Surg. 2016; 32:1–10.

20. Esmaeli B, Ahmadi MA, Youssef A, Diba R, Amato M, Myers JN, Kies M, El-Naggar A. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004; 20:22–26.

21. Williams MD, Al-Zubidi N, Debnam JM, Shinder R, DeMonte F, Esmaeli B. Bone invasion by adenoid cystic carcinoma of the lacrimal gland: preoperative imaging assessment and surgical considerations. Ophthal Plast Reconstr Surg. 2010; 26:403–408.

22. Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016; 38:1258–1262.

23. Bhattasali O, Holliday E, Kies MS, Hanna EY, Garden AS, Rosenthal DI, Morrison WH, Gunn GB, Fuller CD, Zhu XR, Frank SJ. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: a series of 9 cases and a critical review of the literature. Head Neck. 2016; 38:Suppl 1. E1472–E1480.

24. Bell D, Sniegowski MC, Wani K, Prieto V, Esmaeli B. Mutational landscape of lacrimal gland carcinomas and implications for treatment. Head Neck. 2016; 38:Suppl 1. E724–E729.

25. Dennie T. Metastatic, her-2 amplified lacrimal gland carcinoma with response to lapatinib treatment. Case Rep Oncol Med. 2015; 2015:262357.

26. Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011; 22:385–390.

27. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W. European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011; 364:1920–1931.

28. Lee JY, Paik JS, Yun M, Lee SB, Yang SW. The effect of (-)-epigallocatechin-3-gallate on IL-1β induced IL-8 expres-sion in orbital fibroblast from patients with thyroid-associated ophthalmopathy. PLoS One. 2016; 11:e0148645.

29. Yoon JS, Lee HJ, Choi SH, Chang EJ, Lee SY, Lee EJ. Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One. 2011; 6:e26261.

30. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002; 346:1692–1698.

31. Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves' orbitopathy. J Clin Endocrinol Metab. 2013; 98:4291–4299.

32. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015; 100:432–441.

33. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, Smith TJ. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008; 181:5768–5774.

34. Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005; 24:117–119.

35. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2005; 19:1286–1289.